BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) responds to treatment with corticosteroids, intravenous immunoglobulin, and plasma exchange. We aimed to test whether the standard immunosuppressive drug methotrexate was of use in treatment of CIDP. METHODS: In a pilot, multicentre, randomised, double-blind, controlled trial we compared oral methotrexate 7.5 mg weekly for 4 weeks, then 10 mg weekly for 4 weeks, and finally 15 mg weekly for 32 weeks (40 weeks' total treatment) with placebo in patients with CIDP requiring intravenous immunoglobulin or corticosteroids. After about 16 weeks, the dose of corticosteroids or intravenous immunoglobulin was decreased by 20% every 4 weeks if participants did not deteriorate. Primary outcome was a greater than 20% reduction in mean weekly dose in the last 4 weeks of the trial compared with the first 4 weeks. Secondary outcomes analysed separately at the mid-trial and final visits measured activity limitations and strength. Analyses were done by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN73774524. FINDINGS: 59 of the 60 enrolled participants completed the trial. 14 (52%) of 27 taking methotrexate and 14 (44%) of 32 taking placebo had a greater than 20% reduction in mean weekly dose of corticosteroids or intravenous immunoglobulin (adjusted odds ratio 1.21, 95% CI 0.40-3.70). There were no clinically and statistically significant differences in secondary outcomes. The one serious adverse event in the placebo group and the three in the methotrexate group were not thought to be related to treatment. INTERPRETATION: Oral methotrexate 15 mg weekly showed no significant benefit, but limitations in the trial design and the high rate of response in the placebo group meant that a treatment effect could not be excluded. This study can inform design of future trials in CIDP. FUNDING: The GBS/CIDP Foundation International.

Pilot Randomised Controlled Trial of Methotrexate for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (RMC Trial) / M. Mahdi-Rogers, C. Rutterford, R.A. Hughes, J.M. Léger, E. Nobile-Orazio, P. Van den Bergh, P. van Doorn, I.N. van Schaik, R.A. Hughes, R.D. Hadden, E. Choy, M. Reilly, J. Winer, E. Evers, I.N. van Schaik, P.A. van Doorn, J.M. Léger, E. Nobile-Orazio, P. Van den Bergh, A. Créange, A. Gueguen, D. Uzenot, J.M. Léger, A. Behin, G. Nicolas, V. Pautot, A. Uncini, C. Manzoli, G. Lauria, D. Pareyson, E. Nobile-Orazio, C. Casellato, M. Sabatelli, A. Conte, M. Luigetti, C. Briani, M. Lucchetta, A. Schenone, L. Benedetti, E. Fiorina, P.A. van Doorn, E. Brusse, I.N. van Schaik, A.J. van der Kooi, R.A. Hughes, R.D. Hadden, M. Mahdi-Rogers, R.J. Guiloff, W.P. Rakowicz, B.R. Lecky, C.F. Dougan, D. Marshall, J. Winer, N. Davies, M. Busby, A. Lansbury, J. Overell, H.J. Willison, Y.A. Rajabally, B. Kendall, M. Reilly, D. Gow, J. Nixon, O. Kulkarni, H. Katifi, S. Hammans, A. Gibson, C. McDermott, D.R. Cornblath, V. Chaudry, RMC Trial Group. - In: LANCET NEUROLOGY. - ISSN 1474-4422. - 8:2(2009 Feb), pp. 158-164.

Pilot Randomised Controlled Trial of Methotrexate for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (RMC Trial)

E. Nobile-Orazio;G. Lauria;
2009

Abstract

BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) responds to treatment with corticosteroids, intravenous immunoglobulin, and plasma exchange. We aimed to test whether the standard immunosuppressive drug methotrexate was of use in treatment of CIDP. METHODS: In a pilot, multicentre, randomised, double-blind, controlled trial we compared oral methotrexate 7.5 mg weekly for 4 weeks, then 10 mg weekly for 4 weeks, and finally 15 mg weekly for 32 weeks (40 weeks' total treatment) with placebo in patients with CIDP requiring intravenous immunoglobulin or corticosteroids. After about 16 weeks, the dose of corticosteroids or intravenous immunoglobulin was decreased by 20% every 4 weeks if participants did not deteriorate. Primary outcome was a greater than 20% reduction in mean weekly dose in the last 4 weeks of the trial compared with the first 4 weeks. Secondary outcomes analysed separately at the mid-trial and final visits measured activity limitations and strength. Analyses were done by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN73774524. FINDINGS: 59 of the 60 enrolled participants completed the trial. 14 (52%) of 27 taking methotrexate and 14 (44%) of 32 taking placebo had a greater than 20% reduction in mean weekly dose of corticosteroids or intravenous immunoglobulin (adjusted odds ratio 1.21, 95% CI 0.40-3.70). There were no clinically and statistically significant differences in secondary outcomes. The one serious adverse event in the placebo group and the three in the methotrexate group were not thought to be related to treatment. INTERPRETATION: Oral methotrexate 15 mg weekly showed no significant benefit, but limitations in the trial design and the high rate of response in the placebo group meant that a treatment effect could not be excluded. This study can inform design of future trials in CIDP. FUNDING: The GBS/CIDP Foundation International.
Settore MED/26 - Neurologia
feb-2009
Article (author)
File in questo prodotto:
File Dimensione Formato  
Lancet Neurology RMC.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 166.03 kB
Formato Adobe PDF
166.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/70719
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 149
  • ???jsp.display-item.citation.isi??? 120
social impact